Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Henry T Quach; Anna K Dewan; Elizabeth J Davis; Kristin K Ancell; Run Fan; Fei Ye; Douglas B Johnson

doi:10.1001/jamaoncol.2019.0046

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046.

Authors

Henry T Quach¹, Anna K Dewan², Elizabeth J Davis³, Kristin K Ancell³, Run Fan⁴, Fei Ye⁴, Douglas B Johnson³

Affiliations

¹ Vanderbilt University School of Medicine, Nashville, Tennessee.
² Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

Abstract

This cohort study of patients with advanced melanoma treated with anti–programmed cell death 1 with or without ipilimumab assessed whether cutaneous toxic effects were associated with superior clinical outcomes.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Drug Eruptions / etiology
Exanthema / chemically induced
Female
Humans
Ipilimumab / adverse effects
Male
Melanoma / drug therapy*
Middle Aged
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Pruritus / chemically induced
Retrospective Studies
Skin Neoplasms / drug therapy*
Treatment Outcome
Vitiligo / chemically induced
Young Adult

Substances

Antineoplastic Agents, Immunological
Ipilimumab
PDCD1 protein, human
Programmed Cell Death 1 Receptor

Grants and funding

K12 CA090625/CA/NCI NIH HHS/United States